Furthermore, IFN-γ showed signs of functional impairment in patients with CPA, and a randomized controlled trial is underway to assess the addition of IFN-γ to antifungal therapy [20,21] (clinicaltrials.gov; NCT05653193). The gene discussed is IFNG; the disease is congenital primary aphakia.